ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2023
Evaluation of the Prognostic Value of Existing Scoring Systems for Nosocomial Infection in Patients with Decompensated Liver Cirrhosis.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- AI-Based Models for Risk Prediction in MASLD: A Systematic Review.Digestive diseases and sciences · 2026Pooled it
- Admission Plasma Lipopolysaccharide-binding protein, Procalcitonin, and Lactate for Early Identification of Nosocomial Infection in Cirrhotic Patients With Upper Gastrointestinal Bleeding: A Retrospective Analysis.The Kaohsiung journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany scoring systems have been developed to evaluate the severity and survival of end-stage liver disorder patients. However, the conduction of these different predicting models has not been thoroughly verified in cirrhotic patients with nosocomial infections. This study ended to compare the predictive accuracy of various scoring systems.
methodsDuring January 2015 and January 2020, liver cirrhosis patients with nosocomial infections were involved in this study. The clinical data, laboratory findings, and demographic characteristics of patients were collected during diagnosis. Patients were followed up for at least 6 months or till death.
resultsOne hundred thirty-one patients meeting the criteria were enrolled and followed up for at least 6 months. The mortality rate at 30 days, 3 months, and 6 months was 23%, 35.1%, and 39.6%, respectively. The univariate analysis showed that all scoring systems indicated statistical significance between the surviving group and the non-surviving group at 6 months. Model for end-stage liver disease-Na showed excellent predictive accuracy in predicting the survival at 30 days, 3 months, 6 months, with the area under the curve of 0.807, 0.850, and 0.844, respectively. Model for end-stage liver disease-Na demonstrated sensitivities of more than 85%. In contrast, the child-turcotte-pugh and albumin-bilirubin scores showed a poorer predictive capability.
conclusionAll 5 models for end-stage liver disease-related scores (model for end-stage liver disease, model for end-stage liver diseaseto-serum sodium ratio, model for end-stage liver disease-Na, model for end-stage liver disease-Delta, snd integrated model for endstage liver disease) exhibited a reliable prediction for mortality of long-term prognosis and short-term prognosis of cirrhotic patients with nosocomial infections. Among them, the model for end-stage liver disease-Na score might be the best choice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.